A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
|Articles|March 20, 2015
Novartis/Sandoz Clear to Market Their Biosimilar Zarxio
Zarxio was approved earlier this month, the first biosimilar to be approved in the United States.
Advertisement
A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of
In his ruling, U.S. District Judge Richard Seeborg, of San Francisco federal court, denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first approved biosimilar in the United States.
Link to the report on Reuters:
Advertisement
Related to this article
Machine learning models for upper extremity soft tissue sarcoma had a C-index of 0.79 for local recurrence, similar to nomograms, in a 188-patient cohort.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5